



1635 ✓

PTO/SB/21 (01-08)

Approved for use through 01/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	08/978,634
	Filing Date	November 25, 1997
	First Named Inventor	Rabbani
	Art Unit	1635
	Examiner Name	D. Shin
Total Number of Pages in This Submission	Attorney Docket Number	ENz53(D2)

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Information Disclosure Statement Transmittal Letter, 3 Foreign Patent Documents and 43 non-patent documents +fee (charge to deposit acct no. 05-1135).
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	


Please charge fee set forth in 37 CFR 1.17(p) to deposit acct. no. 05-1135

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	The Law Offices of Cheryl H. Agris, Ph.D., P.C.		
Signature	<i>Cheryl H. Agris</i>		
Printed name	Cheryl H. Agris		
Date	January 9, 2008	Reg. No.	34,086

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature	<i>Cheryl H. Agris</i>		
Typed or printed name	Cheryl H. Agris	Date	January 9, 2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Attorney Docket No.: ENZ53(D2)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rabbani et al.

Application No.: 08/978,634

Group Art Unit: 1635

Filed: November 25, 1997

Examiner: D. Shin

For: **MULTIMERIC COMPLEX COMPOSITIONS AND DELIVERY
PROCESSES USING SAME**

Confirmation No.: 4640

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith further references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

Form PTO/SB08a lists US and foreign patent documents and non patent literature that have not been made of record. Some of these foreign patent documents and non-patent literature have been submitted previously. Those submitted herewith are listed below:

Foreign Patents

WO9528494 1995-10-26 Overell et al.
WO9508635 1995-03-30 Craig et al.

01/11/2000 EHAILE1 00000005 051135 08978634
01 FC:1806 180.00 DA

WO9506129 1995-03-02 Craig et al.

Non-patent documents

VERMA Nature 389: 239-242. 1997

FISHER Neurobiology of Disease 4: 1-22. 1997

DATTA et al. Mol. Cell Biol. 16: 1085-1093. 1996

BENNET et al. pp 13-46 in Methods in Molecular Medicine: Antisense Therapeutics
Ed. S. Agrawal, Humana Press, Inc. Totowa NJ 1996

WANG et al., Proc. Natl. Acad. Sci. USA 92: 3318-3322. 1995

THIMME et al., Virology 211: 296-301. 1995

SUN et al. Proc. Natl. Acad. Sci. USA 92: 7272-7276. 1995

ROSSI, Trends Biotechnol. 13: 301-306. 1995

RAMIREZ et al., Virology 206: 57-68. 1995

PARDRIDGE et al., Proc. Natl. Acad. Sci. USA 92: 5592-5596. 1995

MILLER et al., FASEB J. 9: 190-199. 1995

LIMJOCO et al. Virology 208: 75-83. 1995

LAU et al., Hum Gene Ther. 6: 1145-1151. 1995

BINKLEY et al. Nucleic Acids Res. 23: 3198-3205. 1995

ALLY et al., J. Immunol. 155: 5404-5408. 1995

AGRAWAL et al., Biochem. Pharmacol. 50: 571-576. 1995

VIEILLARD et al. Proc. Natl. Acad. Sci. USA 91: 2689-2693. 1994

LEWIN in Genes V, pp 914-915. 1994

JUNKER et al. Antisense Res. Dev. 4: 165-172. 1994

DE YOUNG et al. Biochemistry 33: 12127-12138. 1994

CROOKE, Antisense Res. and Development 4: 145-146. 1994

VLASSOV et al., FEBS Lett. 327: 271-274. 1993

COX et al. Advan. Enzyme Regul. 33: 27-36. 1993

BALVAY et al. BioEssays 15: 165-169. 1993

ALLAWAY et al. AIDS Res. Human Retroviruses 9: 581-587. 1993

ZAIA et al., Annals of the NY Acad Sci 660: 95-106. 1992

IZANT in Gene Regulation: Biology of Antisense RNA and DNA pp 183-195.
Raven Press, Ltd. New York 1992

DUMONTET et al. La Revue de Medecine Intern. 13: 460-464. 1992.

BURKLY et al., J. Immunol. 149: 1779-1787. 1992

PILCH et al. Gene Expression 1: 41-53. 1991

FARUQI et al., Virology 183: 764-768. 1991

YAMASHITA et al. Agric. Biol. Chem. 54: 2801-2809. 1990

FISCHER et al. Science 249: 786-790. 1990.

YOSHIMATSU et al. Science 244: 1346-1348. 1989

VOS et al. Mol. Cell. Biol. 9: 2897-2905. 1989

GATERMANN et al. Mol. Cell Biol. 9: 1526-1535. 1989

NEUMAN DE VEGVAR Nucleic Acids Res. 17: 9305-9318. 1989

BEBENEK et al. J. Biol. Chem. 264: 16948-16956. 1989

OLD et al., Blackwell Scientific Publications, London, 1986

DAVIS et al., Elsevier, NY 1986

PERBAL, John Wiley & Sons, New York, 1984

MANIATIS et al., Cold Spring Harbor Laboratory Press, 1982

ANDERSON et al. Nature 290: 754-758. 1981

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The Information Disclosure Statement submitted herewith is being filed

☐ after submitting the RCE but before any subsequent Office Action

☐ before the mailing date of a first Office Action on the merits

☒ after the mailing date of a first Office Action on the merits. Please charge the fee of \$180 to deposit account no. 05-1135.

Respectfully submitted,

Date: 1/9/2008

C Cheryl H. Agris

Cheryl H. Agris, Reg. No. 34,086
(914) 712-0093



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	08978634
Filing Date	1997-11-25
First Named Inventor	Rabbani
Art Unit	1635
Examiner Name	D. Shin
Attorney Docket Number	Enz-53-D2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

Charge Deposit Aect NO. 65-1135

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	<i>Cheryl H. Agis</i>	Date (YYYY-MM-DD)	<i>2008-01-09</i>
Name/Print	Cheryl H Agis	Registration Number	34086

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.